Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Verdicts against social media companies carry consequences. But questions linger - 2Russian military plane crashes in annexed Crimea, killing 29 people on board
- 3Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- 4Reactions as Artemis II astronauts lift off on historic lunar mission
- 5Supportive Tips On Home loans For First-Time Home Purchasers
- Employers and staff feel effect of fuel price rise
- Palestinians protest against Israel's new death penalty law
- SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- Vote In favor of Your #1 Compelling Female Producer
- Vote In favor of Your Number one Sort Of Blossoms
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- Iran fires one of largest barrages in weeks ahead of Passover
- Step by step instructions to Analyze Senior Insurance Contracts Really.
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
